ulcerative colitis
Gastroenterology · 2013–2025
54decisions
14medicines
37carried consumer input
291individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| adalimumab Immune-mediated inflammatory diseases (IMIDs) in paediatric patients, including juvenile idiopathic arthritis, Crohn disease, ulcerative colitis, psoriasis,… | Jul 2025 | Deferred | 6 individuals |
| infliximab Rheumatoid arthritis, psoriatic arthritis, Crohn's disease (adults and children 6-17 years), refractory Crohn's disease, ankylosing spondylitis, psoriasis, and… | Jul 2025 | Recommended with restriction | input received Colitis Australia |
| infliximab Biosimilar to reference infliximab for multiple indications: rheumatoid arthritis, psoriatic arthritis, Crohn's disease (adults and children/adolescents 6–17… | Mar 2025 | Recommended with restriction | input received Australasian Society of Clinical Immunology and Allergy |
| infliximab Continuing treatment and balance of supply of infliximab 120 mg subcutaneous injection for ankylosing spondylitis, severe Crohn disease, severe chronic plaque… | Mar 2025 | Recommended with restriction | input received Australasian Society of Clinical Immunology and Allergy |
| ustekinumab Biosimilar to Stelara for severe chronic plaque psoriasis, severe psoriatic arthritis, severe Crohn disease, complex refractory fistulising Crohn disease, and… | Mar 2025 | Recommended | input received |
| vedolizumab Dose escalation from 8-weekly to 4-weekly maintenance treatment in adults with moderate to severe ulcerative colitis or severe Crohn disease who have… | Nov 2025 | Recommended with restriction | input received Colitis Australia |
| adalimumab Biosimilar adalimumab for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic… | Jul 2024 | Recommended with restriction | none received |
| adalimumab Complex refractory fistulising Crohn disease, severe Crohn disease, moderate to severe ulcerative colitis, moderate to severe hidradenitis suppurativa, and… | Mar 2024 | Recommended with restriction | input received Colitis Australia |
| etrasimod Treatment of patients 16 years and older with moderate to severe ulcerative colitis (MSUC). | Mar 2024 | Recommended with restriction | input received Colitis Australia |
| ustekinumab Treatment of paediatric severe chronic plaque psoriasis, severe Crohn disease, moderate to severe ulcerative colitis, complex refractory fistulising Crohn… | Mar 2024 | Recommended with restriction | input received Colitis Australia |
| ustekinumab Severe chronic plaque psoriasis (adult and paediatric), severe psoriatic arthritis, severe Crohn disease, complex refractory fistulising Crohn disease, and… | Nov 2024 | Recommended with restriction | input received Colitis Australia |
| mirikizumab Treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response with, lost response to, or were intolerant to… | Jul 2023 | Recommended with restriction | input received |
| upadacitinib Treatment of moderate to severe ulcerative colitis (MSUC) in adult patients who have failed to achieve an adequate response, or are contraindicated, to… | Jul 2022 | Deferred | input received Colitis Australia |
| ustekinumab Treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response or are intolerant to conventional therapy. | Jul 2022 | Recommended with restriction | 2 individuals Colitis Australia |
| ozanimod Treatment of moderate to severe ulcerative colitis in adults who have had an inadequate response, lost response, or were intolerant to prior therapies… | Mar 2022 | Recommended with restriction | 1 individuals Colitis Australia · Gastroenterological Society of Australia |
| adalimumab; upadacitinib Change in restriction levels (Authority Required categories) for adalimumab across multiple indications (rheumatoid arthritis, ankylosing spondylitis,… | Nov 2022 | Noted | 1 individuals |
| ozanimod Treatment of moderate to severe ulcerative colitis (MSUC) in adult patients who have had an inadequate response to, lost response to, or were intolerant to… | Nov 2022 | Recommended with restriction | none received |
| adalimumab Biosimilar to Humira for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active rheumatoid arthritis, severe… | Jul 2021 | Recommended with restriction | input received |
| adalimumab Biosimilar to adalimumab for multiple indications including severe Crohn disease, complex refractory fistulising Crohn disease, moderate to severe ulcerative… | Jul 2020 | Recommended with restriction | none received |
| adalimumab Biosimilar to Humira for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic… | Mar 2020 | Recommended | input received Colitis Australia |
| mesalazine Management of an acute episode of mild to moderate ulcerative proctitis (suppository); ulcerative colitis and Crohn disease (granules). | Mar 2020 | Recommended with restriction | 1 individuals Colitis Australia |
| adalimumab Multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, complex refractory… | Nov 2020 | Recommended with restriction | input received Colitis Australia |
| infliximab Treatment of severe active rheumatoid arthritis, moderate to severe ulcerative colitis, and severe refractory Crohn's disease in adult patients via… | Nov 2020 | Recommended with restriction | input received Colitis Australia |
| mesalazine Treatment of mild to moderate ulcerative colitis and maintenance of remission in adults. | Nov 2020 | Recommended | input received Colitis Australia |
| tofacitinib Treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response, lost response, or were intolerant to standard… | Nov 2020 | Recommended with restriction | 50 individuals Colitis Australia |
| vedolizumab Maintenance treatment for patients with moderate to severe ulcerative colitis (MSUC) and severe Crohn's disease (CD) who have responded to induction treatment… | Nov 2020 | Recommended with restriction | input received Colitis Australia |
| infliximab Increase in maximum quantity from 4 to 5 vials for subsequent continuing treatment of severe Crohn disease, complex refractory fistulising Crohn disease,… | Mar 2019 | Recommended with restriction | 3 individuals |
| tofacitinib Treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response, lost response, or were intolerant to standard… | Mar 2019 | Recommended with restriction | 7 individuals |
| adalimumab Biosimilar of adalimumab for all indications for which Humira is currently PBS listed, including severe active rheumatoid arthritis, severe psoriatic… | Jul 2018 | Recommended with restriction | 1 individuals |
| adalimumab Multiple indications including severe Crohn's disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, fistulising Crohn's… | Jul 2018 | Recommended with restriction | none received |
| adalimumab Treatment of severe Crohn's disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, fistulising Crohn's disease, moderate… | Jul 2018 | Recommended with restriction | none received |
| mesalazine Treatment of ulcerative colitis and Crohn disease in patients with documented hypersensitivity reaction to sulphonamides or intolerance to sulfasalazine. | Jul 2018 | Recommended | none received |
| budesonide Induction of remission in adult patients with mild to moderate active ulcerative colitis where 5-ASA treatment is not sufficient or not tolerated. | Jul 2017 | Not recommended | input received Colitis Australia · Gastroenterological Society of Australia · Australian Inflammatory Bowel Disease Association |
| mesalazine Treatment of ulcerative colitis, including induction of remission and maintenance therapy in adults with mild to moderate ulcerative colitis and those with… | Mar 2017 | Recommended with restriction | none received |
| balsalazide Treatment of mild-to-moderate active ulcerative colitis, and maintenance of remission, in patients who are intolerant to sulfasalazine. | Nov 2017 | Deferred | none received |
| golimumab Treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response to conventional therapy. | Nov 2017 | Recommended with restriction | 21 individuals Colitis Australia |
| infliximab Change to initial and continuing treatment restrictions for infliximab biosimilar, and application of biosimilar uptake measures for multiple indications… | Nov 2017 | Recommended with restriction | none received |
| adalimumab Treatment of patients with moderate to severe ulcerative colitis (UC). Restricted to patients 18 years old and older who have failed to achieve adequate… | Mar 2016 | Not recommended | 3 individuals |
| infliximab Biosimilar infliximab for the same indications as Remicade: rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis,… | Nov 2016 | Recommended with restriction | none received |
| adalimumab Treatment of moderate to severe ulcerative colitis (UC) after failure of conventional agents (5-aminosalicylic acid compounds, corticosteroids, and… | Jul 2015 | Not recommended | 74 individuals Colitis Australia · Australian Inflammatory Bowel Disease Association · Gastroenterological Society of Australia |
| infliximab Biosimilar to Remicade, indicated for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis, and Crohn's disease. | Jul 2015 | Recommended with restriction | 2 individuals |
| vedolizumab Treatment of moderate to severe ulcerative colitis in patients who have failed conventional therapy (5-aminosalicylates, corticosteroids, immunomodulators) or… | Mar 2015 | Not recommended | 98 individuals |
| adalimumab Treatment of moderate to severe ulcerative colitis in patients aged 18 years and older who have failed conventional therapy with 5-aminosalicylates,… | Nov 2015 | Not recommended | 3 individuals Australian Inflammatory Bowel Disease Association · Gastroenterological Society of Australia and Crohn's · Colitis Australia |
| mesalazine Treatment of ulcerative colitis in patients with hypersensitivity to sulfonamides or intolerance to sulfasalazine. | Nov 2015 | Recommended | none received |
| adalimumab Treatment of chronic refractory moderately to severely active ulcerative colitis in adult patients who have failed, are intolerant to, or have… | Jul 2014 | Not recommended | 12 individuals Gut Foundation |
| infliximab Treatment of moderate to severe ulcerative colitis in patients who have had an inadequate response to conventional therapy (5-aminosalicylates, azathioprine,… | Jul 2014 | Recommended | 4 individuals |
| vedolizumab Initial treatment of moderate to severe ulcerative colitis in patients who have failed to achieve adequate response to prior systemic therapy with… | Jul 2014 | Not recommended | 2 individuals |
| infliximab Treatment of moderate to severe ulcerative colitis in patients aged 6 and above who have failed conventional therapy. | Mar 2014 | Recommended with restriction | unclear |
| mesalazine Treatment of active mild to moderate ulcerative colitis and maintenance of remission in patients with hypersensitivity to sulphonamides or intolerance to… | Nov 2014 | Recommended with restriction | no section in document |
| mesalazine Treatment of ulcerative colitis where hypersensitivity to sulphonamides exists or where intolerance to sulfasalazine exists. | Nov 2014 | Recommended with restriction | no section in document |
| budesonide Treatment of active rectal and rectosigmoid disease in ulcerative colitis. | Jul 2013 | Recommended | no section in document |
| infliximab Treatment of acute severe ulcerative colitis not responding to intravenous corticosteroids in patients aged 6 years or greater. | Mar 2013 | Not recommended | unclear |
| adalimumab Moderate to severe active ulcerative colitis in adult patients who have had inadequate response to conventional therapy or who are intolerant to or have… | Nov 2013 | Not recommended | no section in document |
| infliximab Treatment of acute severe ulcerative colitis not responding to intravenous corticosteroids in patients aged 6 years or older. | Nov 2013 | Recommended with restriction | input received |
Who spoke
Colitis Australia · Australian Inflammatory Bowel Disease Association · Gastroenterological Society of Australia · Australasian Society of Clinical Immunology and Allergy · Gastroenterological Society of Australia and Crohn's · Gut Foundation
What the PBS pays
$1,664M in government benefit over 2024–25, across 4,116,996 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ustekinumab | $538.3M |
| upadacitinib | $291.6M |
| adalimumab | $241.9M |
| vedolizumab | $182.8M |
| budesonide | $102.1M |
| golimumab | $97.7M |
| infliximab | $83.8M |
| mesalazine | $62M |
| tofacitinib | $57.8M |
| ozanimod | $4.4M |
| balsalazide | $1.1M |
| etrasimod | $1M |
Appraised elsewhere
NICE, in England and Wales, has appraised 12 technologies for this condition, recommending 12 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| guselkumabGuselkumab for treating moderately to severely active ulcerative colitis | TA1094 | recommended | 2025-08 |
| risankizumabRisankizumab for treating moderately to severely active ulcerative colitis | TA998 | recommended restricted | 2024-08 |
| etrasimodEtrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over | TA956 | recommended | 2024-03 |
| mirikizumabMirikizumab for treating moderately to severely active ulcerative colitis | TA925 | recommended restricted | 2023-10 |
| upadacitinibUpadacitinib for treating moderately to severely active ulcerative colitis | TA856 | recommended | 2023-01 |
| ozanimodOzanimod for treating moderately to severely active ulcerative colitis | TA828 | recommended restricted | 2022-10 |
| filgotinibFilgotinib for treating moderately to severely active ulcerative colitis | TA792 | recommended | 2022-06 |
| ustekinumabUstekinumab for treating moderately to severely active ulcerative colitis | TA633 | recommended restricted | 2020-06 |
| tofacitinibTofacitinib for moderately to severely active ulcerative colitis | TA547 | recommended restricted | 2018-11 |
| vedolizumabVedolizumab for treating moderately to severely active ulcerative colitis | TA342 | recommended restricted | 2015-06 |
| infliximab adalimumab and golimumabInfliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy | TA329 | recommended restricted | 2015-02 |
| infliximabInfliximab for acute exacerbations of ulcerative colitis | TA163 | recommended restricted | 2008-12 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| sulfasalazinePYRALIN EN Sulfasalazine 500mg tablet | 1991 | 3 |
| olsalazineDIPENTUM olsalazine sodium 500mg tablet bottle | 1991 | 2 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 36 of 50 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.